日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)

一项研究旨在调查单价 Omicron LP.8.1 适应性 BNT162b2 COVID-19 疫苗在 ≥ 65 岁成人和 18-64 岁高危成人中的安全性和免疫原性(初步结果)

Dadhe, Rucha; Gayed, Juleen; Iqbal, Muneeb; Solan, Rohit; Wu, Han; Ma, Hua; Xu, Xia; Mensa, Federico J; Belanger, Todd; Cooper, David; Mogg, Robin; Anderson, Annaliesa S; Türeci, Özlem; Şahin, Uǧur; Allen, Pirada Suphaphiphat; Modjarrad, Kayvon; Gurtman, Alejandra; Lindert, Kelly

Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines

BNT162b2 JN.1 和 KP.2 改良型 COVID-19 疫苗的免疫学和生物物理学特征

Chen, Wei; Tompkins, Kristin R; Windsor, Ian W; Martinez, Lyndsey T; Ramos, Minah; Li, Weiqiang; Shrivastava, Shikha; Rajput, Swati; Chang, Jeanne S; Sahasrabudhe, Parag; Fennell, Kimberly F; McLellan, Thomas J; West, Graham M; Dizon, Kristianne P; Yam, Aaron; Mitra, Siddartha; Saha, Subrata; Sharaf, Daiana; McKeen, Andrew P; Cadima, Carla I; Muik, Alexander; Swanson, Wesley; Munoz Moreno, Raquel; Mendoza Daroca, Pilar; Sahin, Ugur; Anderson, Annaliesa S; Wu, Huixian; Swanson, Kena A; Modjarrad, Kayvon

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

单价 Omicron KP.2 适应性 BNT162b2 COVID-19 疫苗在成人中的安全性和免疫原性:一项 2/3 期试验的单臂子研究

Diya, Oyeniyi; Gayed, Juleen; Lowry, Francine S; Ma, Hua; Bangad, Vishva; Mensa, Federico; Zou, Jing; Xie, Xuping; Hu, Yanping; Cutler, Mark; Belanger, Todd; Cooper, David; Xu, Xia; Mogg, Robin; Türeci, Özlem; Şahin, Uǧur; Swanson, Kena A; Modjarrad, Kayvon; Anderson, Annaliesa S; Gurtman, Alejandra; Kitchin, Nicholas

Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection

利用瞬时转染法生产临床级SARS-CoV-2刺突蛋白铁蛋白纳米颗粒免疫原

Hajduczki, Agnes; Chang, William C; De La Barrera, Rafael; Wood, James F; Chen, Wei-Hung; Martinez, Elizabeth J; Jensen, Jaime L; Sankhala, Rajeshwer S; Smith, Clayton; Anderson, Alexander; Morrison, Elaine B; Peterson, Caroline E; Rees, Phyllis A; Soman, Sandrine; Kuklis, Caitlin; Ahmed, Aslaa; King, Jocelyn; Nasar, Farooq; Corbitt, Courtney; Choe, Misook; Thomas, Paul V; Zemil, Michelle; Wieczorek, Lindsay; Polonis, Victoria R; Dooley, Helen M; Mascola, John R; de Val, Natalie; Matyas, Gary R; Rao, Mangala; Gromowski, Gregory D; Modjarrad, Kayvon; Vasan, Sandhya; Froude, Jeffrey W; Michael, Nelson L; Joyce, M Gordon; Zarling, Stasya

Mitigating the surge of mpox in Africa: capacity building through public outreach, sample and case management training for healthcare workers and veterinarians

缓解非洲疥疮疫情激增:通过公众宣传、样本和病例管理培训,加强医护人员和兽医的能力建设

Iroezindu, Michael Onyebuchi; Tiamiyu, Abdulwasiu Bolaji; Parker, Zahra Folasade; Bartolanzo, Danielle; Akinwale, Edward Abayomi; McCauley, Melanie Diane; Amao, Lateefat Kikeloma; Adedeji, Adeyinka Jeremy; Adekanye, Usman Oladipo; Hu, Fengming; Ekweremadu, Chinelo Chidiogo; Ehiakhamen, Odianosen; Onoh, Ikenna; Ogunbode, Oladipo; Akinpelu, Afolabi; Ahmad, Adama; Oladipo-Opashina, Adefunke; Prins, Petra; Amare, Mihret; Keita, Mamadou Bhoye; Kourouma, Kaba; Okeji, Nathan Anelechi Elvis; Chittenden, Laura; Modjarrad, Kayvon; Crowell, Trevor Adam; Collins, Natalie Denise

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

采用含单磷酰脂质A和QS-21的Army脂质体配方佐剂的SARS-CoV-2重组刺突铁蛋白纳米颗粒疫苗:一项I期、随机、双盲、安慰剂对照、首次人体临床试验

Ober Shepherd, Brittany L; Scott, Paul T; Hutter, Jack N; Lee, Christine; McCauley, Melanie D; Guzman, Ivelese; Bryant, Christopher; McGuire, Sarah; Kennedy, Jessie; Chen, Wei-Hung; Hajduczki, Agnes; Mdluli, Thembi; Valencia-Ruiz, Anais; Amare, Mihret F; Matyas, Gary R; Rao, Mangala; Rolland, Morgane; Mascola, John R; De Rosa, Stephen C; McElrath, M Juliana; Montefiori, David C; Serebryannyy, Leonid; McDermott, Adrian B; Peel, Sheila A; Collins, Natalie D; Joyce, M Gordon; Robb, Merlin L; Michael, Nelson L; Vasan, Sandhya; Modjarrad, Kayvon

Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria

拉沙病毒在新宿主中的出现:对尼日利亚南部拉沙病毒感染流行病学的深入了解

Happi, Anise Nkenjop; Ogunsanya, Olusola Akinola; Ayinla, Akeemat Opeyemi; Sijuwola, Ayotunde Elijah; Saibu, Femi Mudasiru; Akano, Kazeem; Nwofoke, Cecilia; Elias, Obineche Tobias; Achonduh-Atijegbe, Olivia; Daodu, Richard Olumide; Adedokun, Oluwatobi Abel; Adeyemo, Abraham; Ogundana, Kehinde Ebenezer; Lawal, Omolola Zaheedat; Parker, Edyth; Nosamiefan, Iguosadolo; Okolie, Johnson; Parker, Zahra F; McCauley, Melanie D; Eller, Leigh Anne; Lombardi, Kara; Tiamiyu, Abdulwasiu Bolaji; Iroezindu, Michael; Akinwale, Edward; Njatou, Thierry Lamare Fouapon Assedi; Mebrahtu, Tsedal; Broach, Erica; Zuppe, Anastasia; Prins, Petra; Lay, Jenny; Amare, Mihret; Modjarrad, Kayvon; Collins, Natalie D; Vasan, Sandhya; Tucker, Cynthia; Daye, Sharon; Happi, Christian Tientcha

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Omicron XBB.1.5 适应性 BNT162b2 COVID-19 疫苗的临床前表征

Modjarrad Kayvon, Che Ye, Chen Wei, Wu Huixian, Cadima Carla I, Muik Alexander, Maddur Mohan S, Tompkins Kristin R, Martinez Lyndsey T, Cai Hui, Ramos Minah, Mensah Sonia, Cumbia Brittney, Falcao Larissa, McKeen Andrew P, Chang Jeanne S, Fennell Kimberly F, Huynh Kevin W, McLellan Thomas J, Sahasrabudhe Parag V, Chen Wei, Cerswell Michael, Garcia Miguel A, Li Shilong, Sharma Rahul, Li Weiqiang, Dizon Kristianne P, Duarte Stacy, Gillett Frank, Smith Rachel, Illenberger Deanne M, Efferen Kari Sweeney, Vogel Annette B, Anderson Annaliesa S, Şahin Uğur, Swanson Kena A

Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.

针对SARS-CoV-2刺突蛋白受体结合域上保守易感位点的抗体

Sankhala Rajeshwer S, Dussupt Vincent, Chen Wei-Hung, Bai Hongjun, Martinez Elizabeth J, Jensen Jaime L, Rees Phyllis A, Hajduczki Agnes, Chang William C, Choe Misook, Yan Lianying, Sterling Spencer L, Swafford Isabella, Kuklis Caitlin, Soman Sandrine, King Jocelyn, Corbitt Courtney, Zemil Michelle, Peterson Caroline E, Mendez-Rivera Letzibeth, Townsley Samantha M, Donofrio Gina C, Lal Kerri G, Tran Ursula, Green Ethan C, Smith Clayton, de Val Natalia, Laing Eric D, Broder Christopher C, Currier Jeffrey R, Gromowski Gregory D, Wieczorek Lindsay, Rolland Morgane, Paquin-Proulx Dominic, van Dyk Dewald, Britton Zachary, Rajan Saravanan, Loo Yueh Ming, McTamney Patrick M, Esser Mark T, Polonis Victoria R, Michael Nelson L, Krebs Shelly J, Modjarrad Kayvon, Joyce M Gordon

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

单价 Omicron XBB.1.5 改良型 BNT162b2 COVID-19 疫苗在 12 岁及以上人群中的安全性和免疫原性:一项 2/3 期试验

Gayed, Juleen; Diya, Oyeniyi; Lowry, Francine S; Xu, Xia; Bangad, Vishva; Mensa, Federico; Zou, Jing; Xie, Xuping; Hu, Yanping; Lu, Claire; Cutler, Mark; Belanger, Todd; Cooper, David; Koury, Kenneth; Anderson, Annaliesa S; Türeci, Özlem; Şahin, Uǧur; Swanson, Kena A; Modjarrad, Kayvon; Gurtman, Alejandra; Kitchin, Nicholas